APA (7th ed.) Citation

Eaton, C., Wells, J., Holen, I., Croucher, P., & Hamdy, F. (2004). Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Chicago Style (17th ed.) Citation

Eaton, C., J. Wells, I. Holen, P. Croucher, and F. Hamdy. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.

MLA (9th ed.) Citation

Eaton, C., et al. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.